Metformin
Small molecule targets CFTR, CXCL1, FAP, MMP9, MTOR, SLC19A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Janumet | — | 2009-02-18 | europa.eu ↗ |
| Approved | EU (EMA) | Avandamet | — | 2003-10-20 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | GLUCOPHAGE | — | 1998-10-22 – 2001-04-19 | fda.gov ↗ |
| Approved | US (FDA) | GLUCOPHAGE | — | 1995-03-03 | fda.gov ↗ |
Trials 1,175 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 042 trials | ||||||
| Phase 0 | NCT07699367 | Nov 2026 → Oct 2031 expected | muscular atrophy | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07588932 | May 2026 → Dec 2027 expected | stroke disorder | Spaulding Rehabilitation Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07120971 | Dec 2025 → Sep 2028 expected | bronchopulmonary dysplasia | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 0 | NCT07065591 | Oct 2025 → Apr 2028 expected | osteoarthritis, knee | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07179042 | Sep 2025 → Sep 2030 expected | muscular atrophy | University of Utah | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06185179 | Sep 2024 → May 2029 expected | muscular atrophy | University of Utah | Recruiting | No outcome recorded |
| Phase 0 | NCT06120881 | Apr 2024 → Dec 2026 expected | type 2 diabetes mellitus | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 0 | NCT05680662 | Jan → Dec 2023 | female breast carcinoma, triple-negative breast carcinoma | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 0 | NCT05349474 | Apr 2022 → May 2025 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 0 | NCT05365451 | Apr 2022 → Jul 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT05262257 | Apr 2022 → Dec 2023 | type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03905941 | Aug 2021 → Nov 2024 | polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT04204044 | Nov 2020 → May 2021 | polycystic ovary syndrome | Rashid Latif Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT06628544 | Sep 2020 → Aug 2023 | — | Zhongnan Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03107884 | Aug 2019 → Nov 2026 expected | muscular atrophy | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03618654 | Nov 2018 → Nov 2021 | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03445702 | Oct 2018 → Oct 2020 | type 2 diabetes mellitus | St. Louis University | Completed | No outcome recorded |
| Phase 0 | NCT03916263 | Aug 2018 → Oct 2022 | polycystic ovary syndrome | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 0 | NCT03477162 | May 2018 → Nov 2021 | neoplasm of thorax | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase 0 | NCT03378297 | May 2018 → Jan 2023 | ovarian cancer | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03772262 | Apr → Nov 2018 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT03151772 | Jan 2018 → Sep 2020 | glioblastoma | Sahlgrenska University Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT03117517 | Mar → Aug 2017 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 0 | NCT01422746 | Mar 2017 → Dec 2024 | obesity disorder, polycystic ovary syndrome | University of Virginia | Unknown | No outcome recorded |
| Phase 0 | NCT02981329 | Mar 2017 → Jul 2020 | sickle cell disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT03109873 | Jan 2017 → Jul 2020 | laryngeal disorder, oral cavity cancer, pharynx neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT02823691 | Apr 2016 → Dec 2021 | neuroendocrine neoplasm | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 0 | NCT02498522 | Aug 2015 → Feb 2016 | polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT02587741 | Jul 2015 → Jul 2023 | diabetic retinopathy | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 0 | NCT02153450 | May 2015 → Aug 2018 | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02308228 | Jan 2015 → Dec 2017 | — | Philip Kern | Completed | No outcome recorded |
| Phase 0 | NCT02402348 | Dec 2014 → Aug 2016 | head and neck cancer | West Virginia University | Terminated | No outcome recorded |
| Phase 0 | NCT02184832 | Aug 2014 → Mar 2016 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 0 | NCT01980823 | Oct 2013 → May 2018 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT02083692 | Sep 2013 → May 2016 | head and neck squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT01793948 | Apr 2013 → Jan 2018 | breast cancer, obesity disorder | Anna Maria Storniolo | Completed | No outcome recorded |
| Phase 0 | NCT01685762 | Jan 2013 → Dec 2015 | endometrial hyperplasia without atypia | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01911247 | May 2011 → Feb 2013 | endometrial cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01302002 | Jan 2011 → Feb 2016 | breast cancer | Brazilian National Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT01205672 | Sep 2010 → May 2017 | endometrial cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01465113 | May 2010 → Feb 2016 | Barrett esophagus | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01037660 | Sep 2005 → Dec 2015 | cardiovascular disorder | Boston University | Completed | No outcome recorded |
| Phase 1320 trials | ||||||
| Phase 1 | NCT07511010 | Oct 2026 expected | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07275359 | Sep 2026 → Sep 2028 expected | chronic obstructive pulmonary disease | Duke University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300059 | Jul → Aug 2026 overdue | — | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07396844 | Jul 2026 overdue | — | LG Chem | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300046 | Jun → Aug 2026 overdue | — | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07570082 | May → Dec 2026 expected | — | Crinetics Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07550816 | May → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07567781 | Apr → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07530289 | Apr → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07300020 | Apr → Jun 2026 overdue | — | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
| Show all 320 trials opens the full record — a long page | ||||||
| Phase 1/235 trials | ||||||
| Phase 1/2 | NCT07666698 | Jul 2026 → Jul 2027 expected | heart failure | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07395960 | Sep 2025 → Sep 2026 expected | cognitive impairment with or without cerebellar ataxia, obesity disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06871904 | Apr → Dec 2025 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 1/2 | NCT06845540 | Feb → May 2025 overdue | hyperpigmentation of the skin | University of Puerto Rico | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06332612 | Aug → Dec 2024 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 1/2 | NCT06030622 | Apr → Dec 2024 | malignant pancreatic neoplasm | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT06090227 | Dec 2023 → Nov 2027 expected | focal segmental glomerulosclerosis | Yale University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05759312 | Mar 2023 → Feb 2025 | ovarian clear cell cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05036226 | Mar 2022 → May 2027 expected | prostate cancer | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04767841 | Feb 2021 → Jun 2024 | osteoarthritis, knee | Sadat City University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04530747 | Jan → Nov 2021 | obstructive sleep apnea syndrome | Pennington Biomedical Research Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04545736 | Nov 2020 → Feb 2028 expected | ABCA4-related retinopathy, Stargardt disease | National Eye Institute (NEI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04536805 | Nov 2020 → Nov 2031 expected | prostate cancer | Institut Cancerologie de l'Ouest | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04377451 | Jul 2020 → Jun 2023 | dengue disease, obesity disorder, phenformin 4-hydroxylation | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 1/2 | NCT04121468 | Feb 2020 → Mar 2027 expected | multiple sclerosis | The Hospital for Sick Children | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04268563 | Jan 2020 → Jul 2021 | infertility disorder, polycystic ovary syndrome | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT04141163 | Oct 2019 → Mar 2021 | fragile X syndrome | Rowan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04068246 | Aug 2019 → Dec 2020 | rheumatoid arthritis | Sadat City University | Completed | No outcome recorded |
| Phase 1/2 | NCT03772964 | Jan 2019 → Mar 2020 | inflammatory disease | Brian Zuckerbraun | Completed | No outcome recorded |
| Phase 1/2 | NCT03757923 | Jun → Dec 2018 | menstrual disorder | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02949700 | Jan 2017 → Jun 2021 | head and neck squamous cell carcinoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT04088448 | Jan 2017 → Jun 2020 | major depressive disorder | Sadat City University | Completed | No outcome recorded |
| Phase 1/2 | NCT02496741 | Nov 2015 → Nov 2019 | chondrosarcoma, glioma, intrahepatic cholangiocarcinoma | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT02495103 | Aug 2015 → Feb 2020 | leiomyomatosis, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT02143050 | Sep 2014 → Nov 2017 | melanoma | University of Louisville | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02179788 | Jun 2014 → Jul 2016 | lactation disease, prediabetes syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT01804842 | Dec 2012 → Apr 2013 | type 2 diabetes mellitus | Elcelyx Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01638676 | Jul 2012 → Jun 2025 overdue | melanoma | University of Louisville | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01677299 | May → Sep 2012 | type 2 diabetes mellitus | Elcelyx Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01488552 | Nov 2011 → Aug 2015 | pancreas disorder | Pancreatic Cancer Research Team | Completed | No outcome recorded |
| Phase 1/2 | NCT00390273 | Dec 2006 → Oct 2007 | lactic acidosis | Centre de Recherche en Nutrition Humaine Rhone-Alpe | Completed | No outcome recorded |
| Phase 1/2 | NCT00425009 | Jan → Dec 2004 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01084486 | — | NAFLD1 | Wolfson Medical Center | Completed | No outcome recorded |
| Phase 2245 trials | ||||||
| Phase 2 | NCT07647003 | Oct 2026 → May 2027 expected | hypertensive disorder | NuSirt Biopharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07139405 | Sep 2026 → Sep 2027 expected | type 2 diabetes mellitus | Myopharm Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07007221 | Jul 2026 → Dec 2030 | HIV infectious disease, depressive disorder | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT07693452 | Jun 2026 → Feb 2028 expected | pseudomyxoma peritonei | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 2 | NCT07226453 | May 2026 → Apr 2028 expected | posterior fossa group A ependymoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT07291297 | Mar 2026 → Oct 2028 expected | soft tissue sarcoma | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07387900 | Feb 2026 → Sep 2027 expected | oral mucosa leukoplakia | Cairo University | Recruiting | No outcome recorded |
| Phase 2 | NCT07129473 | Jan 2026 → Jan 2030 expected | hyperemesis gravidarum | University of Southern California | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06463743 | Sep 2025 → Jan 2027 expected | multiple sclerosis | State University of New York at Buffalo | Recruiting | No outcome recorded |
| Phase 2 | NCT05607316 | Jul 2025 → Jun 2028 | vitiligo | University of Massachusetts, Worcester | Withdrawn | No outcome recorded |
| Show all 245 trials opens the full record — a long page | ||||||
| Phase 2/327 trials | ||||||
| Phase 2/3 | NCT07033585 | Jun 2025 → Oct 2026 expected | type 2 diabetes mellitus | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT07092618 | Dec 2024 → Aug 2025 overdue | — | AgelessRx | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06691542 | Nov 2024 → Mar 2025 overdue | verrucous papilloma | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06080802 | Nov 2023 → Nov 2024 | diastolic heart failure, type 2 diabetes mellitus | October University for Modern Sciences and Arts | Unknown | No outcome recorded |
| Phase 2/3 | NCT06766201 | Aug 2023 → Sep 2024 | periodontitis | Postgraduate Institute of Dental Sciences Rohtak | Completed | No outcome recorded |
| Phase 2/3 | NCT05373680 | Jan 2022 → Apr 2024 | chronic kidney disease | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04409795 | Aug 2021 → Dec 2024 | monogenic diabetes, type 1 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT04098666 | Mar 2021 → Apr 2026 overdue | cognitive impairment with or without cerebellar ataxia | Columbia University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05638893 | Feb 2021 → Mar 2022 | osteoarthritis, knee | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04607252 | Jan → Jun 2021 | atypical endometrial hyperplasia | Fudan University | Terminated | No outcome recorded |
| Phase 2/3 | NCT04387630 | Jun 2020 → Jun 2022 | breast cancer | Mansoura University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03452267 | Sep 2019 → Dec 2024 | — | Wayne State University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04500678 | Feb 2019 → Feb 2022 | HIV infectious disease | University of Hawaii | Unknown | No outcome recorded |
| Phase 2/3 | NCT03129113 | Mar 2017 → Nov 2020 | HIV infectious disease, fatty liver disease | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT02882477 | Dec 2016 → May 2018 | diabetes mellitus, iron metabolism disease, optic atrophy, peptic ulcer disease +2 | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2/3 | NCT03981861 | Jul 2016 → Jul 2018 | polycystic ovary syndrome | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 2/3 | NCT02065687 | Mar 2014 → Apr 2019 | endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma | Gynecologic Oncology Group | Unknown | No outcome recorded |
| Phase 2/3 | NCT01690091 | Nov 2012 → May 2016 | heart failure | Institute for Clinical and Experimental Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT01319994 | Jul 2012 → Aug 2014 | exogenous Cushing syndrome | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT01217307 | Jan 2011 → Oct 2013 | ST-elevation myocardial infarction, coronary artery disorder, diabetes mellitus, heart failure | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2/3 | NCT01855763 | Dec 2008 → Dec 2013 | gestational diabetes, type 2 diabetes mellitus | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT00362765 | Oct 2006 → Jul 2007 | hyperlipidemia, type 2 diabetes mellitus | Solvay Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/3 | NCT00268476 | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01087866 | Jun 2005 → Aug 2009 | gestational diabetes | University of Oulu | Completed | No outcome recorded |
| Phase 2/3 | NCT00303537 | Nov 2004 → Jun 2008 | fatty liver disease | University Hospital, Aker | Unknown | No outcome recorded |
| Phase 2/3 | NCT04148183 | Jan 2004 → Jan 2005 | — | J JESUS VENEGAS, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT00209482 | Oct 2003 → Nov 2007 | obesity disorder | Glaser Pediatric Research Network | Unknown | No outcome recorded |
| Phase 3148 trials | ||||||
| Phase 3 | NCT07520110 | Aug 2026 → Mar 2029 expected | idiopathic pulmonary fibrosis | University of Massachusetts, Worcester | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06405178 | Mar 2026 | polycystic ovary syndrome | Beni-Suef University | Completed | No outcome recorded |
| Phase 3 | NCT07630779 | Mar → Sep 2026 expected | polycystic ovary syndrome | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 3 | NCT07136987 | Jan 2026 → Jan 2031 expected | tuberculosis | Open Source Pharma Foundation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06999343 | Sep 2025 → May 2029 expected | chronic obstructive pulmonary disease | Fundación Instituto de Investigación Sanitaria de Navarra | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07120815 | Sep 2025 → Dec 2027 expected | polycystic ovary syndrome | Helsinki University Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07475546 | Jul 2025 → Apr 2026 overdue | — | AgelessRx | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07297290 | Jul 2025 → Mar 2027 expected | obesity disorder | University Of Nigeria Teaching Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06836128 | Mar 2025 → Feb 2026 overdue | polycystic ovary syndrome | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07280572 | Feb 2025 → Dec 2027 expected | post-COVID-19 disorder | Janneke van de Wijgert | Enrolling by invitation | No outcome recorded |
| Show all 148 trials opens the full record — a long page | ||||||
| Phase 4217 trials | ||||||
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07696806 | Jul 2026 → Jun 2027 expected | hyperpigmentation of the skin | Sameh Sarsik | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07485764 | Jun 2026 overdue | obesity disorder, psoriasis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07323381 | Dec 2025 → Sep 2027 expected | type 2 diabetes mellitus | Bin Lu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06862739 | Oct 2025 → Apr 2026 overdue | type 2 diabetes mellitus | Nabiqasim Industries (Pvt) Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT07442006 | Oct 2025 → Mar 2027 expected | type 2 diabetes mellitus | JW Pharmaceutical | Recruiting | No outcome recorded |
| Phase 4 | NCT06707012 | Oct 2025 → Jun 2026 overdue | depressive disorder | Fazaia Ruth Pfau Medical College | Recruiting | No outcome recorded |
| Phase 4 | NCT04523363 | Jun 2025 → Jun 2026 | prediabetes syndrome | Gianna Wilkie | Withdrawn | No outcome recorded |
| Phase 4 | NCT06851962 | May 2025 → Jun 2026 overdue | type 2 diabetes mellitus | Fundación para la Investigación del Hospital Clínico de Valencia | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06937294 | Apr → Dec 2025 overdue | chronic pancreatitis | Changhai Hospital | Recruiting | No outcome recorded |
| Show all 217 trials opens the full record — a long page | ||||||
| Phase not applicable141 trials | ||||||
| — | NCT07495748 | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07485777 | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07654179 | Jun 2026 → Jun 2027 expected | depressive disorder, obesity disorder | Riphah International University | Recruiting | No outcome recorded |
| — | NCT07589387 | May 2026 → Apr 2029 expected | diabetes mellitus | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07497568 | Nov 2025 → Mar 2027 expected | — | University of Baghdad | Recruiting | No outcome recorded |
| — | NCT07215156 | Oct 2025 → Apr 2026 overdue | chronic periodontitis | Kafrelsheikh University | Not yet recruiting | No outcome recorded |
| — | NCT06907472 | Sep 2025 → Jun 2026 overdue | type 2 diabetes mellitus | University of Abuja | Active not recruiting | No outcome recorded |
| — | NCT07108075 | Jun → Oct 2025 overdue | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT06965868 | Jun 2025 → Feb 2027 expected | mental disorder | Leibniz Institute for Resilience Research | Not yet recruiting | No outcome recorded |
| — | NCT07380841 | May → Nov 2025 | metabolic syndrome X, polycystic ovary syndrome | Islamabad Medical and Dental College | Completed | No outcome recorded |
| Show all 141 trials opens the full record — a long page | ||||||
Also used as a comparator or background therapy in 905 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 013 trials | ||||||
| Phase 0 | NCT07209527 Background | Oct 2025 → Oct 2028 expected | abdominal obesity-metabolic syndrome, chronic kidney disease, hyperlipidemia, hypertensive disorder +3 | Truway Health, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05917587 Comparator | Sep 2024 → Dec 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT06452511 Comparator | Aug 2024 → Mar 2025 | polycystic ovary syndrome | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | Completed | No outcome recorded |
| Phase 0 | NCT06772857 Background | Jul → Aug 2024 overdue | — | Cairo University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05515978 Comparator | Oct 2022 → Oct 2035 expected | prostate cancer | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 0 | NCT03681197 Comparator | Jun 2018 → Apr 2019 | infertility disorder | Elham Raafat | Unknown | No outcome recorded |
| Phase 0 | NCT02689843 Comparator | Feb → Nov 2018 | polycystic ovary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03566225 Comparator | Jan 2018 → Feb 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT03349775 Comparator | Nov 2017 → Dec 2020 | obesity disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 0 | NCT02844803 Background | Jul 2016 → Jun 2017 | diabetes mellitus | Namyi Gu | Unknown | No outcome recorded |
| Phase 0 | NCT02341703 Comparator | Feb → Jul 2015 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT01909141 Comparator | Aug 2013 → Feb 2014 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT02026869 Comparator | Jan → Jun 2013 | polycystic ovary syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT07459595 Comparator | May → Jul 2026 overdue | polycystic ovary syndrome | Fatima Tariq | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06424860 Comparator | Nov 2025 → Dec 2026 expected | atherosclerotic cardiovascular disease, polycystic ovary syndrome | University of Alberta | Recruiting | No outcome recorded |
| Phase 1 | NCT07603505 Comparator | Apr 2025 → May 2026 | infertility disorder, metabolic disease, polycystic ovary syndrome | Jinnah Sindh Medical University | Completed | No outcome recorded |
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07399535 Comparator | Feb 2025 → Feb 2026 | infertility disorder, metabolic disease, polycystic ovary syndrome | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 1 | NCT07375654 Comparator | Dec 2024 → Oct 2025 | psoriasis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT06045351 Background | Jan 2024 → Jun 2026 overdue | anovulation | Aga Khan University | Recruiting | No outcome recorded |
| Phase 1 | NCT05760677 Background | Oct 2022 → Sep 2023 | polycystic ovary syndrome, type 2 diabetes mellitus | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 1 | NCT06170463 Comparator | Aug 2022 → Mar 2023 | polycystic ovary syndrome | Zagazig University | Completed | No outcome recorded |
| Phase 1 | NCT05065372 Comparator | Jul 2022 → Mar 2027 expected | cardiovascular disorder, diabetic kidney disease, type 1 diabetes mellitus | Kalie Tommerdahl | Recruiting | No outcome recorded |
| Phase 1 | NCT04047940 Comparator | Nov 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04070794 Comparator | Nov 2019 | type 2 diabetes mellitus | LG Chem | Unknown | No outcome recorded |
| Phase 1 | NCT03216278 Comparator | Sep 2017 → May 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02803918 Background | May 2017 → Jan 2020 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02956044 Comparator | Nov 2016 → Mar 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT02670018 Comparator | Aug → Dec 2015 | — | LG Life Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT02411825 Background | Mar 2015 → Jan 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02366377 Background | Feb 2015 → Mar 2016 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02244567 Comparator | Sep 2014 → Jun 2021 | polycystic ovary syndrome | Beni-Suef University | Unknown | No outcome recorded |
| Phase 1 | NCT02048384 Comparator | Jun 2014 → Feb 2018 | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT02113163 Comparator | Mar → Jun 2014 | hypertriglyceridemia, type 2 diabetes mellitus | Thetis Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 1 | NCT02026817 Comparator | Dec 2013 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02011633 Comparator | Oct → Nov 2013 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01929512 Comparator | Jun → Aug 2013 | diabetes mellitus | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01845077 Comparator | May → Aug 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02088918 Comparator | Oct → Dec 2012 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02291510 Comparator | Oct → Dec 2012 | — | Elcelyx Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01725672 Comparator | Sep 2012 → Aug 2013 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02682121 Comparator | Apr 2012 → Jan 2017 | prediabetes syndrome | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT02749032 Comparator | Nov 2011 → Mar 2014 | type 2 diabetes mellitus | Michael A. Nauck | Completed | No outcome recorded |
| Phase 1 | NCT01154348 Background | Jun → Nov 2010 | type 2 diabetes mellitus | Shionogi | Completed | No outcome recorded |
| Phase 1 | NCT01232036 Comparator | May → Aug 2010 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00961909 Background | Jun 2009 → Oct 2010 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00971659 Comparator | Jan → Sep 2008 | type 2 diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00546741 Comparator | Nov 2007 → Feb 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00975052 Comparator | Jan → Mar 2006 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00865072 Comparator | Aug 2003 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864734 Comparator | Nov 2002 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT03686657 Comparator | Dec 2026 → Dec 2030 | arthritic joint disease, hypertensive disorder, obesity disorder, type 2 diabetes mellitus | ARKAY Therapeutics | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06806345 Background | Jan → Mar 2025 overdue | metabolic syndrome X | Cairo University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05279768 Comparator | Sep 2022 → Jan 2025 | polycystic ovary syndrome | PT. Prodia Stem Cell Indonesia | Completed | No outcome recorded |
| Phase 1/2 | NCT05215990 Comparator | Jan → Dec 2022 | pulmonary tuberculosis | Mahidol University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04623567 Comparator | Dec 2021 → Dec 2023 | hyperlipidemia, type 2 diabetes mellitus | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT04973891 Comparator | Apr → Jul 2021 | polycystic ovary syndrome | Shengjing Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02960659 Background | May 2017 → May 2022 | type 2 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 1/2 | NCT02755844 Background | Sep 2016 → Nov 2018 | endometrial cancer | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 1/2 | NCT01804049 Comparator | Apr 2014 → Aug 2018 | prediabetes syndrome | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1/2 | NCT02020616 Background | Dec 2013 → Feb 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1/2 | NCT01329016 Comparator | Jul 2011 → Feb 2015 | gestational diabetes | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 1/2 | NCT01786707 Background | Jul 2009 → Mar 2011 | type 2 diabetes mellitus | Rodolfo Alejandro | Completed | No outcome recorded |
| Phase 1/2 | NCT01396564 Comparator | Oct 2005 → Oct 2006 | type 2 diabetes mellitus | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 1/2 | NCT01043965 Comparator | Aug 2005 → Aug 2009 | type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 2133 trials | ||||||
| Phase 2 | NCT05910554 Comparator | Dec 2025 → Jun 2027 | pulmonary sarcoidosis | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 2 | NCT06948825 Comparator | Oct 2025 → Nov 2026 expected | gestational diabetes | George Washington University | Recruiting | No outcome recorded |
| Phase 2 | NCT07182526 Background | Sep 2025 → May 2026 overdue | polycystic ovary syndrome | Al-Mustansiriyah University | Recruiting | No outcome recorded |
| Phase 2 | NCT05426044 Comparator | Jun 2025 → Dec 2027 expected | glaucoma | Christopher Kai Shun Leung | Recruiting | No outcome recorded |
| Phase 2 | NCT06995339 Comparator | May 2025 → Aug 2026 overdue | gout | Mostafa Bahaa | Recruiting | No outcome recorded |
| Show all 133 trials opens the full record — a long page | ||||||
| Phase 2/342 trials | ||||||
| Phase 2/3 | NCT06975111 Comparator | Mar 2026 → Oct 2029 expected | cardiovascular disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07229651 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07585396 Comparator | May 2025 → May 2026 | infertility disorder, polycystic ovary syndrome | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 2/3 | NCT05646199 Comparator | Mar → Sep 2025 | polycystic ovary syndrome | University of Hull | Unknown | No outcome recorded |
| Phase 2/3 | NCT06896981 Background | Feb → Oct 2025 overdue | obesity disorder, polycystic ovary syndrome | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06728982 Comparator | May 2024 → Jun 2025 | rectal cancer | Minia University | Completed | No outcome recorded |
| Phase 2/3 | NCT06181422 Comparator | Apr → Jun 2024 | infectious disease with sepsis | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06140108 Comparator | Dec 2023 → May 2024 | polycystic ovary syndrome | SINA Health Education and Welfare Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT06142656 Comparator | Nov 2023 → Dec 2025 overdue | polycystic ovary syndrome | October 6 University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06125587 Comparator | Nov 2023 → Oct 2024 | polycystic ovary syndrome | Shengjing Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05412056 Comparator | Jun 2022 → Jun 2025 | pregnancy disorder | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2/3 | NCT04998032 Background | Oct 2021 → Jun 2023 | type 2 diabetes mellitus | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT04852510 Comparator | Feb 2019 → Aug 2020 | polycystic ovary syndrome | Saudi German Hospital - Madinah | Completed | No outcome recorded |
| Phase 2/3 | NCT03056274 Comparator | Jan → Jun 2019 | intrahepatic cholestasis of pregnancy, pregnancy disorder | Epsom and St Helier University Hospitals NHS Trust | Unknown | No outcome recorded |
| Phase 2/3 | NCT03507413 Comparator | Sep 2018 → May 2024 | abdominal aortic aneurysm | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2/3 | NCT03968224 Comparator | Aug 2018 → Jul 2024 | morbid obesity, prediabetes syndrome, type 2 diabetes mellitus | Centro Medico Nacional Siglo XXI IMSS | Completed | No outcome recorded |
| Phase 2/3 | NCT03479476 Comparator | Apr 2018 → May 2024 | X-linked intellectual disability, chromosomal disorder, fragile X syndrome | University of California, Davis | Completed | No outcome recorded |
| Phase 2/3 | NCT04879511 Comparator | Feb 2018 → Jan 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT03008551 Comparator | Aug 2017 → Apr 2018 | polycystic ovary syndrome | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT03355469 Comparator | Aug 2017 → Mar 2024 | metabolic syndrome X | Rutgers University | Completed | No outcome recorded |
| Phase 2/3 | NCT02786823 Background | May → Aug 2017 | type 2 diabetes mellitus | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 2/3 | NCT03204058 Comparator | Feb 2016 → Feb 2017 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT03204071 Comparator | Feb 2016 → Feb 2017 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02802215 Comparator | Jan → Aug 2016 | gestational diabetes, polycystic ovary syndrome | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02064881 Comparator | Oct 2015 → Apr 2020 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02580331 Comparator | Nov 2014 → Sep 2015 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT03167918 Background | Jul 2014 → Apr 2017 | type 2 diabetes mellitus | Liaoning University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT02461667 Comparator | Jul 2014 → Mar 2015 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02372656 Comparator | Dec 2013 → Aug 2014 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02274090 Comparator | Nov 2013 → Aug 2014 | periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT01666665 Comparator | Nov 2012 → Aug 2018 | hyperglycemia | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 2/3 | NCT01664845 Comparator | Aug 2012 → Aug 2014 | chronic hepatitis C virus infection | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| Phase 2/3 | NCT01273584 Comparator | Oct 2010 → Jul 2015 | obesity disorder, pregnancy disorder | Epsom and St Helier University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT00900146 Background | Apr 2009 → Nov 2010 | type 2 diabetes mellitus | Novartis | Terminated | No outcome recorded |
| Phase 2/3 | NCT00940472 Comparator | Mar → Dec 2009 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 2/3 | NCT00683735 Comparator | Feb 2009 → Dec 2012 | type 2 diabetes mellitus | Michael A. Nauck | Completed | No outcome recorded |
| Phase 2/3 | NCT00860288 Background | Feb 2009 → Mar 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT01318135 Comparator | Jan 2009 → Jan 2010 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2/3 | NCT01318109 Comparator | Aug 2008 → Apr 2009 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2/3 | NCT00734474 Background | Aug 2008 → Jun 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/3 | NCT00349128 Background | Jan 2004 → ? | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT01394887 Comparator | Jul 2002 → Jul 2003 | diabetes mellitus, glucose intolerance | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 3283 trials | ||||||
| Phase 3 | NCT06560333 Comparator | Nov 2026 → Apr 2027 | type 2 diabetes mellitus | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07057479 Background | Sep 2026 → Feb 2028 | type 2 diabetes mellitus | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07635953 Comparator | Jul 2026 → Jul 2029 expected | diabetes mellitus | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07622290 Comparator | Jun 2026 → Aug 2027 expected | asthma | Prof Ibrahim Janahi | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07395895 Comparator | Mar → Apr 2026 overdue | — | Badr University | Not yet recruiting | No outcome recorded |
| Show all 283 trials opens the full record — a long page | ||||||
| Phase 4264 trials | ||||||
| Phase 4 | NCT07342764 Comparator | Sep 2026 → Nov 2028 expected | — | Sultan Qaboos University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07289750 Comparator | May 2026 → Aug 2027 expected | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07173712 Comparator | Mar 2026 → Jun 2027 expected | type 2 diabetes mellitus | Yanbing Li | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07436182 Comparator | Mar → Jun 2026 overdue | — | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07452913 Comparator | Jan → Mar 2026 overdue | type 2 diabetes mellitus | Bahria University | Enrolling by invitation | No outcome recorded |
| Show all 264 trials opens the full record — a long page | ||||||
| Phase not applicable118 trials | ||||||
| — | NCT07687667 Comparator | Jul 2026 → Dec 2028 expected | female infertility, obesity disorder, polycystic ovary syndrome | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07696585 Comparator | Jun → Sep 2026 expected | alopecia areata | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07604779 Comparator | May → Dec 2026 expected | polycystic ovary syndrome | Beni-Suef University | Active not recruiting | No outcome recorded |
| — | NCT07460336 Background | May 2026 → Dec 2027 expected | latent autoimmune diabetes in adults | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| — | NCT07516821 Comparator | Apr → Jul 2026 overdue | psoriasis | Cairo University | Not yet recruiting | No outcome recorded |
| Show all 118 trials opens the full record — a long page | ||||||
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-18 | Novartis Pharmaceuticals | Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin novartis.com ↗ |
| 2017-05-15 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Glumetza® in the United States tevapharm.com ↗ |
| 2016-09-15 | Pfizer | Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes pfizer.com ↗ |
| 2015-09-28 | Takeda | Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina ® and Metformin Hydrochloride for the Treatment of Type 2 Diabetes in Japan takeda.com ↗ |
| 2005-10-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Glipizide and Metformin HCL Tablets tevapharm.com ↗ |
| 2005-04-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Metformin Hcl Extended Release Tablets, 750 Mg tevapharm.com ↗ |
| 2005-01-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Glyburide/Metformin Hcl Tablets tevapharm.com ↗ |
| 2004-12-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Metformin Hcl Extended Release Tablets, 750 Mg tevapharm.com ↗ |
| 2004-06-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Metformin Hcl Er Tablets tevapharm.com ↗ |
| 2003-03-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Metformin HCl Extended-Release Tablets tevapharm.com ↗ |
| 2002-01-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Metformin Tablets tevapharm.com ↗ |
Evidence & citations 73 cited values
Every value below carries the sentence it was read from. 2,108 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MetFORMIN | “Besides the glucose lowering effect by reducing hepatic glucose output and improving insulin resistance, metformin without inhibiting DPP-4 activity,also increases active GLP-1...” NCT02188186 ↗2008“In addition to the routine treatment (metformin), patients will receive a second drug orally for 12 weeks: the METV group will receive metformin plus vildagliptin (50 mg twice...” PMID 25366037 ↗ Nov 2014 “The secondary objective is to assess in healthy Chinese subjects, the safety and tolerability of the SHR3824 and Metformin after single doses (administered in the fed and...” NCT05120219 ↗ “This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic...” PMID 33345876 ↗ May 2020 “Metformin 500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior...” NCT04300790 ↗ “A Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of...” NCT02039258 ↗ “Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg)...” NCT05657613 ↗ “Step 1: Metformin 500 mg daily Step 2: Metformin 1000 mg daily Step 3: Metformin 1000 mg twice daily Step 4: Metformin 1000 mg twice daily + glibenclamide 5 mg daily Step 5:...” NCT06907472 ↗ “Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet...” NCT01535677 ↗ “The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of...” NCT05641337 ↗ “those in group B will get insulin (Humulin R) subcutaneously whose dose can be adjusted within 24 hours according to blood sugar levels, whereas those in group A will receive...” NCT07582471 ↗ “To assess the effect of food on the pharmacokinetics (PK) of canagliflozin and metformin following administration of a canagliflozin/metformin (150/1,000 mg) immediate-release...” PMID 25546166 ↗ Mar 2015 “Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for...” NCT06693934 ↗ “The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS-0200) on body weight and obesity comorbidities in a...” PMID 30569637 ↗ Jan 2019 “Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations” NCT01106651 ↗ “The intervention group is administered metformin sustained-release tablets (taken once daily, 1500mg each time; if intolerable, the dosage was reduced to the maximum tolerated dose).” NCT07395960 ↗ “Metformin administered orally starting at 500 mg once daily and titrated over two weeks to a maximum dose of 1500 mg/day (500 mg three times daily), taken after meals for 6 months.” NCT07630779 ↗ “Metformin, have been used for metabolic abnormalities in schizophrenia, findings from these studies indicated that they did have some effect,which are still in experimental stage.” NCT03708549 ↗ “The primary objective of the study is to evaluate the efficacy of metformin vs placebo, on the improvement of muscle function in patients with DM1 compared to its placebo.” NCT05532813 ↗ “Each woman in the three groups will receive medical treatment (metformin tablets) for eight weeks and the dose will prescribed by the gynecologist during the first visit.” NCT06882291 ↗ “Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes” NCT04128995 ↗ “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ “The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.” NCT05692934 ↗ “Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks.” NCT05035849 ↗ “Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used.” NCT03972982 ↗ “Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).” NCT01426737 ↗ “Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)” NCT02039245 ↗ “combined rosiglitazone/metformin (Avandametä) to placebo in subjects with normal or intermediate fasting glucose (IFG) and stable coronary artery disease.” NCT00343395 ↗ “metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition.” NCT06836128 ↗ “This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.” NCT06273072 ↗ “Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.” NCT01922492 ↗ “In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks.” NCT03353948 ↗ “This group is given metformin 500 miligram three times a day (glucophage 500mg, Merck company, Turkey) (total dose of metformin 1500 miligram a day)” NCT05951309 ↗ “Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.” NCT00776607 ↗ “This study evaluated the glycemic effects and safety of metformin delayed-release (Metformin DR), which targets metformin delivery to the ileum” PMID 30252913 ↗ Sep 2018 “SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin.” NCT02616666 ↗ “Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.” NCT01241669 ↗ “Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.” NCT03317028 ↗ “Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment” NCT02564926 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.” NCT01087567 ↗ “Sentagliptin Phosphate 50 mg, once daily, plus metformin hydrochloride extended-release tablets (50 mg, two or three times daily).” NCT07241897 ↗ “Avandamet contains two drugs commonly used to control blood sugar levels in patients with diabetes (metformin and rosiglitazone).” NCT00933309 ↗ “Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported.” PMID 20124139 ↗ Feb 2010 “Since Metformin is frequently prescribed for reducing IR and hence the treatment for anovulatory infertility in these females” NCT03989778 ↗ “Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.” NCT05369793 ↗ “OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗ “two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin” NCT03364335 ↗ “Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast” NCT05823870 ↗ “Two tablets 550 mg L-leucine + 250 mg metformin and one tablet 1.0 mg sildenafil per dose; 3 tablets/dose orally BID” NCT07647003 ↗ “Antihyperglycemic drugs: biguanides "Metformin" - 0.5 g two or tree times per day, or "Exenatide" - 5-10 µg per day.” NCT01700075 ↗ “Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg” NCT05164263 ↗ “Metformin tablets (Metformin XR, extended release 500 mg, oral tablet, active ingredient: metformin hydrochloride).” NCT07622290 ↗ “the patients with 25kg/m2\<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d)” NCT00147836 ↗ “Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral” NCT03907423 ↗ “A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition” NCT05874180 ↗ “Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition” NCT05823883 ↗ “Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout” NCT05682495 ↗ “GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration” NCT03851341 ↗ “GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration” NCT03927170 ↗ “The combination of glimepiride and metformin is used for glycemic control in patients with diabetes mellitus.” PMID 22036245 ↗ Oct 2011 “Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month” NCT07635953 ↗ “Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).” NCT03813316 ↗ “Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month” NCT06946628 ↗ “combination tablet of SYR-322 and metformin hydrochloride ( hereinafter referred to as SYR-322-MET tablet)” NCT02276274 ↗ “standard care, including dietary and lifestyle modifications and metformin therapy if clinically indicated” NCT07120828 ↗ “PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)” NCT03604419 ↗ “oral anti-diabetic agents (OADs: metformin, sulfonylureas, nateglinide, repaglinide or pioglitazone)” NCT01919489 ↗ “Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.” NCT02201381 ↗ “Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing under fasting condition” NCT05364164 ↗ “500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable” NCT04994561 ↗ “a standard oral hypoglycemic agent (e.g., metformin) as prescribed by their primary care provider” NCT07209527 ↗ “A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers” NCT05874167 ↗ “where they will receive metformin (rescue medication) added onto their blinded study medication” NCT00316082 ↗ “When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added.” NCT00506194 ↗ “sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day” NCT01751321 ↗ “polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)” NCT00133718 ↗ “short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks” NCT03194945 ↗ “Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.” NCT05232994 ↗ “All participants receive 1000 mg of metformin therapy at the beginning of the study.” NCT03983551 ↗ “Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy.” NCT06627322 ↗ “Metformin and placebo will be dispensed every 3 months, both administered orally.” NCT05109169 ↗ “Metformin, Sulfonylureas, Sodium-glucose cotransporter-2 inhibitors, pioglitazone” NCT06243536 ↗ “Metformin Tab. 500mg twice daily for 12 months (titrated to tolerance if needed).” NCT07145827 ↗ “antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid” NCT00691314 ↗ “Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily” NCT01811485 ↗ “Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months” NCT00131664 ↗ “Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day” NCT01841697 ↗ “Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid.” NCT06417489 ↗ “Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)” NCT01582243 ↗ “metformin as add- on therapy for improving the outcome in RRMS patients.” NCT05298670 ↗ “Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg” NCT04233437 ↗ “combination therapy of basal insulin, metformin and vildagliptin” NCT03958591 ↗ “Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg” NCT02946632 ↗ “Group who takes Glimepiride 2mg+Metformin 500mg, once daily.” NCT02823808 ↗ “Metformin (inhibition of hepatic glucose production, 500 mg)” NCT04027023 ↗ “antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid” NCT00664846 ↗ “Personalized combination of somatropin, metformin, and DHEA” NCT04375657 ↗ “Allowed background antidiabetic therapy included metformin” NCT01798706 ↗ “Group A: Dapagliflozin 10 mg once daily + Metformin ± OHAs” NCT07311551 ↗ “Single, oral, 500 mg dose of metformin immediate release” NCT00809536 ↗ “850mg of metformin hydrochloride (HCl) (Glifage®) tablet” NCT05083949 ↗ “Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet” NCT01429506 ↗ “treatment with metformin 1g twice daily will be started.” NCT01974544 ↗ “Antidiabetic: metformin 500 mg bid (max 2000 mg/day).” NCT07088523 ↗ “Lantus (insulin glargine) + Glucophage (Metformin)” NCT00653302 ↗ “single dose of delayed-release metformin (Met DR)” NCT01658514 ↗ “Lobeglitazone Sulfate 0.5mg, Metformin HCl 1000mg” NCT02565368 ↗ “DAPA/extended-release (ER) metformin (DAPA/MET)” PMID 34097062 ↗ Sep 2021 “Metformin hydrochloride delayed-release tablets” NCT05151146 ↗ “Metformin 1.7-2.5mg per day during twelve weeks” NCT05032001 ↗ “MET:CSII combined with metformin 500mg BID-TID.” NCT00948324 ↗ “Metformin 140mg/m2 intravenous infusion, day6;” NCT06682130 ↗ “Dapagliflozin/Metformin (Xigduo XR) 10/1000mg” NCT03826641 ↗ “Metformin, Ethinylestradiol 30µg-Drospirenone” NCT01459445 ↗ “E : Evogliptin 5 mg M : Metformin XR 1000 mg” NCT02375139 ↗ “SAL067 6mg(2 tablet) and Metformin ≥1500mg” NCT05801627 ↗ “Treatment with Metformin once for 30 days” NCT05279768 ↗ “Metformin, Dapagliflozin and Saxagliptin” NCT03700801 ↗ “Lobeglitazone, Empagliflozin, Metformin” NCT06492655 ↗ “18 of whom were on metformin treatment” NCT02006836 ↗ “Evogliptin 5 mg + Metformin XR 1000 mg” NCT02167061 ↗ “Drug: MetFORMIN 500 Mg Oral Tablet” NCT05215990 ↗ “5-mg saxagliptin/1000 mg metformin” NCT01441869 ↗ “metformin delayed-release tablets” NCT01819272 ↗ “metformin delayed-release tablets” NCT01804842 ↗ “insulin with or without metformin” NCT02897349 ↗ “Hypoglycemic drug 'Metformin'” NCT06806345 ↗ “Metformin or Sulphonylurea” NCT03850886 ↗ “sulfonylurea or metformin” NCT00819325 ↗ “metformin and alogliptin” NCT02683226 ↗ “Metformin 1,000mg, BID” NCT06644404 ↗ “metformin (Glucophage)” NCT00000620 ↗ “Metformin 1000mg” NCT07034781 ↗ “Metformin 1000mg” NCT07044765 ↗ “Drug: Metformin” NCT01717313 ↗ “Drug: Metformin” NCT07570082 ↗ “Metformin” NCT00865839 ↗ “Metformin” NCT00865748 ↗ “Metformin” NCT00864669 ↗ “Metformin” NCT03733132 ↗ “metformin” NCT04416269 ↗ “Metformin” NCT03098654 ↗ “metformin” NCT04497792 ↗ |
| Known as | 1,1 dimethylbiguanide | “Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994.” NCT04141163 ↗2“Metformin's chemical name is 1,1-Dimethylbiguanide, a molecular formula of C4H11N5.” NCT07055958 ↗ “Metformin (1,1-dimethylbiguanide) is an oral antihyperglycemic drug.” NCT05468554 ↗ |
| Known as | 1,1-dimethylbiguanide hydrochloride | “Metformin (1,1-dimethylbiguanide hydrochloride) belongs to the biguanide class of oral hypoglycaemic agents” NCT00881725 ↗ |
| Known as | A10BA02 Metformin | “A10BA02 Metformin” NCT01690091 ↗ |
| Known as | Cidophage | “Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy with Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®).” NCT06812585 ↗6“All patients in the combined metformin-CC group received metformin HCl (Cidophage®;Chemical Industries Development,Cairo, Egypt), 500 mg thrice daily for 6-8 weeks.” NCT00969631 ↗ “Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test” NCT05362799 ↗ “Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy” NCT05298670 ↗ “wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.” NCT02562664 ↗ “metformin HCl (Cidophage®; Chemical Industries Development, Egypt)” NCT01008046 ↗ “metformin HCl (Cidophage®; CID,Cairo, Egypt)” NCT00911313 ↗ |
| Known as | CLUCOPHAGE XR | “The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500...” NCT00865839 ↗ |
| Known as | Diabex | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗1“metformin 1500mg plus metformin 500mg or 1000mg (Diabex)” NCT00975065 ↗ |
| Known as | Diaformin | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Dianben | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | dimethylbiguanide | “The antihyperglycemic drug dimethylbiguanide (DMB, also known as metformin) reduces the risk of cardiovascular complications in type 2 diabetes” PMID 11756340 ↗ Jan 2002 |
| Known as | DMB | “The antihyperglycemic drug dimethylbiguanide (DMB, also known as metformin) reduces the risk of cardiovascular complications in type 2 diabetes” PMID 11756340 ↗ Jan 2002 |
| Known as | EFB0026 | “EFB0026 (metformin immediate-release)” NCT01677299 ↗ |
| Known as | EFB0027 | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗1“EFB0027 (metformin delayed release)” NCT01677299 ↗ |
| Known as | ETB0014 | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ |
| Known as | ETB0015 | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ |
| Known as | Extended Release Metformin Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04576104 ↗ |
| Known as | Fortamet | “A new medicine called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal glucose metabolism in diabetics. This randomized study will compare...” NCT00344851 ↗1“It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Gliclazide modified release tablets | “added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max)” NCT02587741 ↗ |
| Known as | Glifage | “850mg of metformin hydrochloride (HCl) (Glifage®) tablet” NCT05083949 ↗ |
| Known as | Glifage XR | “1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg” NCT06560333 ↗ |
| Known as | GLUCOLIFE XR 500 | “The prolonged release metformin tablets 500 mg (Brand Name: GLUCOLIFE XR ® 500) will be provided by QLife Pharma manufacturer, Doha, Qatar.” NCT07622290 ↗ |
| Known as | Glucophage | “Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet...” NCT01535677 ↗31“Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.) was administered at a dose of 0.5 g...” NCT07687667 ↗ “A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects...” NCT00376038 ↗ “IRMCI-2 (diabetic patients): Active Intervention (Intensive lifestyle modification) plus metformin (Glucophage, 250mg thrice daily) or Control group (standard lifestyle...” NCT02409238 ↗ “Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.” NCT07229651 ↗ “The groups are: 1) a lifestyle modification program plus metformin (also known as glucophage), 2) lifestyle modification plus placebo, 3) metformin alone or 4) placebo alone.” NCT00399360 ↗ “Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months” NCT04969627 ↗ “Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.)” NCT06775093 ↗ “Metformin (Glucophage; Bristol-Myers Squibb, Princeton, NJ) is an insulin sensitizer and lowers serum insulin and androgen levels.” NCT00413179 ↗ “Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months.” NCT07586969 ↗ “Patients will receive Metformin 1000 mg once daily orally for 12 weeks (control group) (Glucophage® Merck company)” NCT06576375 ↗ “the patients with 25kg/m2\<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d)” NCT00147836 ↗ “PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)” NCT03604419 ↗ “Metformin was provided by Bristol Myers Squibb in America, trade name: Glucophage, 500 mg/tablet.” NCT02798172 ↗ “Metformin (Glucophage ® 500 tablets twice daily)+ Combined oral contraceptive (standard therapy)” NCT06083935 ↗ “Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended” NCT02710448 ↗ “Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets.” NCT02986659 ↗ “conventional therapy which is Metformin 500 mg film coated tablets (Glucophage).” NCT06229795 ↗ “Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]” NCT02960711 ↗ “Glucophage (Metformin Hydrochloride Tablets)” NCT06932874 ↗ “Metformin hydrochloride (Glucophage®)” NCT00986401 ↗ “metformin hydrochloride or Glucophage” NCT02113163 ↗ “Glucophage ( Metformin Hydrochloride)” NCT02584075 ↗ “Metformin 500mg(Glucophage tablets)” NCT03686722 ↗ “Drug: Glucophage (Metformin)” NCT00736385 ↗ “Metformin (glucophage)” NCT01881828 ↗ |
| Known as | Glucophage 1000 | “The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.” NCT01840007 ↗ |
| Known as | GLUCOPHAGE Sustained Release | “commercially available formulations of metformin extended release (XR) (GLUCOPHAGE ™ Sustained Release” NCT01725672 ↗ |
| Known as | Glucophage (metformin hydrochloride) | “Glucophage (metformin hydrochloride)” NCT05900466 ↗ |
| Known as | Glucophage (Metformin) | “Glucophage (Metformin)” NCT03010683 ↗ |
| Known as | Glucophage SR | “The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection )” NCT03831464 ↗1“Atorvastatin (Lipitor) and Metformin (Glucophage SR)” NCT02378441 ↗ |
| Known as | Glucophage XR | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗6“patients will be treated with metformin extended release (ER) (Glucophage® XR), starting at 750 milligrams (mg) oral (PO) once daily (QD) for 4 days, then escalating to 750 mg...” NCT03477162 ↗ “The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the...” NCT02179788 ↗ “Glucophage XR 750 mg once at dinner for 15 days then twice daily” NCT06045351 ↗ “GLUCOPHAGE® XR 750 mg tablets, single dose” NCT00865852 ↗ |
| Known as | Glucophage XR (metformin hydrochloride) | “Glucophage XR (metformin hydrochloride)” NCT05900466 ↗ |
| Known as | Glucophage XR 1000mg(Metformin) | “Glucophage XR 1000mg(Metformin)” NCT01992211 ↗ |
| Known as | Glucophage, Metformin HCl | “Glucophage, Metformin HCl” NCT01486043 ↗ |
| Known as | GlucophageXR/SR 500 | “Metformin is administered as Glucophage®XR/SR 500, (500 mg oral tablets).” PMID 38297399 ↗ Jan 2024 |
| Known as | Gluformin | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Glumetza | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗1“2x500 mg Metformin (Glumetza)” NCT01845077 ↗ |
| Known as | Met | “Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been...” PMID 36147577 ↗ Sep 202225“The aim of the present study was to evaluate the effects of commonly used treatment regimens such as metformin (MET) or an oral contraceptive pill (OC) containing...” PMID 24554512 ↗ Feb 2014 “Although metformin (MET) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes...” PMID 18761646 ↗ Aug 2008 “The purpose of this study is to assess the effect of coadministration of a high-fat meal on the oral bioavailability of a fixed dose combination of Canagliflozin/extended...” NCT02039258 ↗ “The overarching hypothesis of this study is that vildagliptin (vilda) as add on therapy to metformin (met) in Egyptian type 2 diabetic obese patient will produce an equal, if...” NCT07077525 ↗ “The aim of this trial was to evaluate the efficacy and safety of the combination of once-daily insulin detemir (IDet) and sitagliptin (SITA) versus SITA ± sulphonylurea (SU),...” PMID 21205123 ↗ Mar 2011 “twice-daily biphasic insulin aspart 30 (30% soluble and 70% protaminated insulin aspart; BIAsp 30) plus metformin (met) was compared with once-daily insulin glargine (glarg)...” PMID 17115351 ↗ Oct 2006 “OBJECTIVE: To determine if the combination of lifestyle (caloric restriction and exercise) and metformin (MET) would be superior to lifestyle and placebo (PBO) in improving the...” PMID 21193187 ↗ Dec 2010 “we evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in...” PMID 18460557 ↗ May 2008 “Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination...” NCT01068652 ↗ “Participants were randomly assigned (1:1) to the healthy eating and physical activity (LIFE) or the metformin plus LIFE (MET plus LIFE) interventions, within eight strata...” PMID 41233082 ↗ Dec 2025 “Metformin (MET) has been reported to have antidepressant effects in animal models and in diabetic patients with depression, owing to its anti-inflammatory, antioxidant, and...” PMID 32500486 ↗ Oct 2020 “Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism” NCT06231758 ↗ “Metformin (MET), an insulin sensitizer, is used to ameliorate insulin resistance and associated reproductive endocrine metabolic dysfunctions in PCOS patients.” PMID 41331576 ↗ Dec 2025 “Metformin (MET), by boosting immunity, has been suggested as a host-adjunctive therapy to anti-tuberculosis treatment (ATT).” PMID 38850838 ↗ Jun 2024 “The participants were randomly assigned to 12 weeks of metformin (MET) or acarbose (ACA) treatment combined with insulin.” PMID 36273168 ↗ Oct 2022 “Subjects were randomized to rosiglitazone (RSG) or metformin (MET) for 52 wk followed by 24 wk of open-label MET.” PMID 27052635 ↗ Mar 2016 “Metformin (MET) is often used to treat PCOS but information is limited as to its effects on liver function.” PMID 21832111 ↗ Aug 2011 “One group received JTTZ formula, and the other received metformin (MET) for 12 consecutive weeks.” PMID 29808092 ↗ Apr 2018 “metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.” NCT07058675 ↗ “combination (COMBO) of metformin (MET) 1000 mg BID and liraglutide 1.2 mg QD” PMID 28143456 ↗ Jan 2017 “receiving insulin glargine (GLAR) + metformin (MET).” PMID 20357372 ↗ Mar 2010 “metformin extended-release (MET) initial therapy” PMID 26786577 ↗ Jan 2016 “lifestyle modification (LM) and Metformin (Met)” PMID 34006388 ↗ May 2021 “Group 3 was treated with metformin (MET)” NCT00279240 ↗ “metformin extended release (MET)” PMID 28228317 ↗ Oct 2016 |
| Known as | Met DR | “This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c)...” NCT01819272 ↗3“This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and...” NCT01804842 ↗ “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ “single dose of delayed-release metformin (Met DR)” NCT01658514 ↗ |
| Known as | Met IR | “delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗1“immediate-release metformin (Met-IR)” NCT02791490 ↗ |
| Known as | Met XR | “This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c)...” NCT01819272 ↗2“delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014)” NCT02291510 ↗ “extended-release metformin (Met XR)” NCT01658514 ↗ |
| Known as | MetfoLiquid GeriaSan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04590937 ↗ |
| Known as | Metfor 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA | “Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA” NCT04852510 ↗ |
| Known as | metformin (Glucophage) | “metformin (Glucophage)” NCT00000620 ↗ |
| Known as | Metformin ER | “Metformin ER, one gram three times daily taken orally.” NCT06033131 ↗ |
| Known as | metformin glycinate | “Metformin Glycinate is a novel biguanide compound developed as a potential candidate for the treatment of type 2 diabetes.” NCT01560481 ↗ |
| Known as | Metformin Hcl | “A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone...” NCT00727857 ↗30“One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks” NCT00570739 ↗ “test formulation of Metformin HCl 1000 mg granules manufactured by Indeus Life Sciences Pvt. Ltd., Mumbai India” NCT02217670 ↗ “Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API)” NCT05230758 ↗ “Reference products : Metformin HCl 500mg tablet, Repaglinide 2mg tablet” NCT01780051 ↗ “Tablet Metformin HCl 500 mg per oral twice daily for 12 weeks” NCT05759442 ↗ “Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient” NCT03684707 ↗ “metformin HCl extended release 1000 mg (500mg x 2 tablets)” NCT03355014 ↗ “Metformin HCl 750 mg Extender Release tablets, single dose” NCT00865072 ↗ “Metformin HCl 750 mg Extender Release tablets, single dose” NCT00865852 ↗ “Lobeglitazone Sulfate 0.5mg, Metformin HCl 1500mg” NCT02627027 ↗ “Glipizide and Metformin HCl Tablets 5 mg/500 mg” NCT00648505 ↗ “metformin HCl (Cidophage®; CID,Cairo, Egypt)” NCT00911313 ↗ “Metformin HCl 500 mg tablets, single dose” NCT00865839 ↗ “Metformin HCl 500 mg tablets, single dose” NCT00865748 ↗ “Metformin HCl 500 mg tablets, single dose” NCT00864669 ↗ “glimepiride/metformin HCl 2mg/1000 mg FDC” NCT02395237 ↗ “glimepiride 2 mg & metformin HCl 500 mg” NCT00934817 ↗ “Metformin HCL Tablets, 1000 mg Sandoz” NCT00865033 ↗ “Metformin HCl (standard release)” NCT07436182 ↗ “Metformin Hcl 850Mg Tab” NCT04194424 ↗ “Metformin HCl capsules” NCT01890122 ↗ “Drug: Metformin HCL” NCT00005669 ↗ |
| Known as | metformin HCl extended release | “Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day” NCT01662674 ↗ |
| Known as | Metformin Hydrochloride | “This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after...” NCT01780051 ↗112“The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500...” NCT00865839 ↗ “The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes...” NCT07289750 ↗ “Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of...” NCT00570739 ↗ “Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.) was administered at a dose of 0.5 g...” NCT07687667 ↗ “Patients randomized to metformin treatment will take 750 mg Metformin Hydrochloride tablets once daily for 4 weeks; the dose will be increased to 750 mg twice daily for the...” NCT05426044 ↗ “Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to twice daily through study week-12 (11 weeks total...” NCT04930744 ↗ “The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the...” NCT02179788 ↗ “Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride.” NCT02659306 ↗ “Metformin hydrochloride immediate-release tablet initiated at 500 mg twice daily for 2 weeks then increased to 1000 mg twice daily from Week 3 through Week 12, taken with meals.” NCT07436182 ↗ “Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.” NCT06405971 ↗ “Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fasting condition” NCT04070794 ↗ “Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.” NCT01386671 ↗ “To determine the duration of response to metformin (metformin hydrochloride), carboplatin and paclitaxel followed by maintenance with metformin” NCT02050009 ↗ “Determine the maximum tolerated dose (MTD) of metformin (metformin hydrochloride) in combination with cytarabine in relapsed/refractory AML.” NCT01849276 ↗ “Participants in placebo group will receive an escalating dose of Metformin hydrochloride tablets up to a dose of 2500mg for 10 months.” NCT03733132 ↗ “Patients receive extended-release metformin hydrochloride orally (PO) once daily (QD) on week 1, and twice daily (BID) on weeks 2-12” NCT01447927 ↗ “This randomized clinical trial studies metformin hydrochloride in overweight or obese patients at elevated risk for breast cancer.” NCT01793948 ↗ “Sentagliptin Phosphate 50 mg, once daily, plus metformin hydrochloride extended-release tablets (50 mg, two or three times daily).” NCT07241897 ↗ “Metformin hydrochloride is an oral antihyperglycemic drug not chemically or pharmacologically related to thiazolidinediones.” NCT00727857 ↗ “Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks” NCT00993187 ↗ “Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India” NCT06233240 ↗ “Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India” NCT06233201 ↗ “The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.” NCT01589445 ↗ “Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg.” NCT03467763 ↗ “same glimepiride/metformin hydrochloride (HCl) 2 mg/1000 mg fixed dose combination (FDC) tablets” NCT02395237 ↗ “Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)” NCT03514108 ↗ “Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets.” NCT02986659 ↗ “with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets” NCT02526810 ↗ “Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks” NCT04182321 ↗ “Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD” NCT03039075 ↗ “Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.” NCT05131828 ↗ “IMPORTANCE: Metformin hydrochloride is emerging as a repurposed anticancer drug.” PMID 31486833 ↗ Nov 2019 “metformin hydrochloride (metformin) to alter the cytokine and exosome profiles.” NCT03109873 ↗ “Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride.” NCT01478308 ↗ “Metformin Hydrochloride 1000 mg/day (single daily oral dose) for 8 weeks.” NCT07604870 ↗ “Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)” NCT05729386 ↗ “Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.” NCT05893225 ↗ “Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg” NCT00864734 ↗ “500 mg Metformin Hydrochloride Extended Release Tablets” NCT00864669 ↗ “Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]” NCT02960711 ↗ “5 mg Glipizide/500 mg Metformin Hydrochloride Tablets” NCT00835497 ↗ “oral metformin (metformin hydrochloride) treatment” NCT01312467 ↗ “sitagliptin phosphate (+) metformin hydrochloride” NCT00541450 ↗ “metformin (metformin hydrochloride) and aspirin” NCT02420652 ↗ “one tablet of metformin hydrochloride (500mg)” NCT07362030 ↗ “Metformin Hydrochloride 850 mg oral tablet” NCT06142656 ↗ “Metformin Hydrochloride ER Tablets 750 mg” NCT00648518 ↗ “Metformin Hydrochloride ER Tablets 500 mg” NCT00650234 ↗ “Metformin hydrochloride (Glucophage®)” NCT00986401 ↗ “metformin hydrochloride 500 mg tablet” NCT07372625 ↗ “Glucophage ( Metformin Hydrochloride)” NCT02584075 ↗ “metformin hydrochloride or Glucophage” NCT02113163 ↗ “Drug: Metformin Hydrochloride 850 MG” NCT03618472 ↗ “metformin hydrochloride (metformin)” NCT03048500 ↗ “Comparator: metformin hydrochloride” NCT00449930 ↗ “metformin hydrochloride (metformin)” NCT05237960 ↗ “Drug: Metformin Hydrochloride” NCT06707012 ↗ “Drug: Metformin Hydrochloride” NCT03359681 ↗ “Drug: Metformin Hydrochloride” NCT07380841 ↗ “Drug: Metformin hydrochloride” NCT02231931 ↗ “Drug: Metformin Hydrochloride” NCT04549415 ↗ “Drug: Metformin Hydrochloride” NCT04284722 ↗ “Drug: metformin hydrochloride” NCT00830076 ↗ “Drug: Metformin Hydrochloride” NCT05828303 ↗ “Drug: Metformin hydrochloride” NCT02854527 ↗ “Drug: Metformin Hydrochloride” NCT04221750 ↗ “Drug: Metformin Hydrochloride” NCT05590676 ↗ “Drug: Metformin Hydrochloride” NCT04807348 ↗ “Drug: Metformin Hydrochloride” NCT04530383 ↗ “Drug: Metformin Hydrochloride” NCT06012682 ↗ “Drug: Metformin Hydrochloride” NCT03831464 ↗ “Drug: Metformin Hydrochloride” NCT05177588 ↗ “Drug: Metformin Hydrochloride” NCT04758000 ↗ “Drug: Metformin Hydrochloride” NCT06920056 ↗ “Metformin hydrochloride” NCT05463094 ↗ |
| Known as | Metformin Hydrochloride (HCL) | “The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet” NCT05549583 ↗2“Metformin hydrochloride (HCl) 500mg tablet” NCT05230758 ↗ “Drug: Metformin Hydrochloride (HCL)” NCT05759442 ↗ |
| Known as | Metformin hydrochloride branded as Glucophage | “Metformin hydrochloride branded as Glucophage” NCT01638676 ↗ |
| Known as | MetFORMIN Hydrochloride ER | “Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.” NCT03772964 ↗ |
| Known as | Metformin Hydrochloride Extended-release Tablets | “The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company.” NCT06762223 ↗ |
| Known as | Metformin IR | “Single dose (1000 mg) of metformin IR” NCT05151146 ↗ |
| Known as | Metformin SR | “Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)” NCT01526317 ↗ |
| Known as | metformin sustained release | “A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in...” PMID 25678778 ↗ Feb 2015 |
| Known as | Metformin XR | “Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8...” NCT01234649 ↗19“Two FDC tablets of gemigliptin/metformin 25/500 mg or separate tablets of gemigliptin (50 mg ×1) and metformin XR (500 mg ×2) were orally administered in each period.” PMID 25678778 ↗ Feb 2015 “Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle.” NCT04899349 ↗ “Participants in the Treatment Arm will receive oral extended-release metformin (metformin-XR) 1x daily with an evening meal starting prior to conception.” NCT07129473 ↗ “Metformin tablets (Metformin XR, extended release 500 mg, oral tablet, active ingredient: metformin hydrochloride).” NCT07622290 ↗ “Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.” NCT03710460 ↗ “Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)” NCT00643851 ↗ “1 Metformin XR caplet 750 mg (twice daily)” NCT01733459 ↗ “Metformin XR, 500-2000mg nocte” NCT04511416 ↗ “Metformin XR 1500 mg” NCT00918138 ↗ “Drug: Metformin XR” NCT02915198 ↗ “Drug: Metformin XR” NCT02145559 ↗ |
| Known as | metformin(diabex) | “metformin(diabex)” NCT00474838 ↗ |
| Known as | Metformin: Fortamet, Glucophage | “Metformin: Fortamet, Glucophage” NCT01968317 ↗ |
| Known as | Metformine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00546442 ↗ |
| Known as | metformine HCl | “Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg” NCT02395237 ↗ |
| Known as | Metformini hydrochloridum | “Metformini hydrochloridum (Siofor 1000 tbl, Berlin)” NCT01690091 ↗ |
| Known as | MTF | “Metformin (MTF), a biguanide, usually used in obese patients with type 2 diabetes,inhibits glucose hepatic production,decreases insulin secretion and increases peripheral...” NCT00679679 ↗1“DZX + metformin (DZX + MTF)” PMID 30202851 ↗ Nov 2018 |
| Known as | MXR | “combination with metformin extended release (MXR) or placebo” PMID 27433488 ↗ Nov 2014 |
| Known as | N dimethyl-biguanide | “Metformin (N dimethyl-biguanide) is an anti diabetic drug that increases glucose utilization in insulin sensitive tissues.” NCT01279512 ↗ |
| Known as | N,N-dimethylimidodicarbonimidic diamide | “Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994.” NCT04141163 ↗ |
| Known as | Novolin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01308437 ↗ |
| Known as | Obimet | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Riomet | “It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with...” NCT04141163 ↗ |
| Known as | Siofor 1000 tbl, Berlin | “Metformini hydrochloridum (Siofor 1000 tbl, Berlin)” NCT01690091 ↗ |
| Known as | ultralente | “We conducted a randomized crossover design clinical trial to compare glargine with ultralente insulin as a basal insulin in type 1 diabetes.” PMID 15616226 ↗ Jan 20051“Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗ |
| Known as | ultralente insulin | “To determine whether the use of glargine insulin as a basal insulin would result in a comparable HbA1c and less glycemic variation and hypoglycemia than ultralente insulin, 22...” PMID 15616226 ↗ Jan 2005 |
| Action | Activate | “the therapeutic effects of the drug, which involve activation of AMP-activated protein kinase (AMPK), is unknown.” PMID 17476361 ↗ May 2007 |
| Modality | Small molecule | “Metformin is still the recommended first-line glucose-lowering drug for people with T2DM.” PMID 32501595 ↗ Jun 2020 |
| Route | Oral | “Patients receive oral metformin or oral placebo three times daily for 7 weeks” NCT00005104 ↗ |
| Target | MTOR | “It may be able to block mTOR and slow the growth of tumors.” NCT01087983 ↗ |